10.21147/j.issn.1000-9604.2020.02.09
Phase 1/2 study of concurrent chemoradiotherapy with weekly irinotecan hydrochloride for advanced/recurrence uterine cancer:A multi-institutional study of Kansai Clinical Oncology Group
32
This trial was partially supported by grant of Japanese Foundation for Multidisciplinary Treatment of Cancer JFMC for Cancer Research in 2005 26 th
2020-08-25(万方平台首次上网日期,不代表论文的发表时间)
共10页
218-227